Bemelmans RHH - Search Results

1

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson.

Huygen LPM, Westerink J, Mol GC, Bemelmans RHH. Huygen LPM, et al. Among authors: bemelmans rhh. JACC Case Rep. 2022 Jun 1;4(11):690-693. doi: 10.1016/j.jaccas.2022.03.009. eCollection 2022 Jun 1. JACC Case Rep. 2022. PMID: 35677796 Free PMC article.

2

Vascular and metabolic effects of 12 days intensive walking to Santiago de Compostela.

Bemelmans RH, Coll B, Faber DR, Westerink J, Blommaert PP, Spiering W, Visseren FL. Bemelmans RH, et al. Atherosclerosis. 2010 Oct;212(2):621-7. doi: 10.1016/j.atherosclerosis.2010.06.012. Epub 2010 Jun 11. Atherosclerosis. 2010. PMID: 20598693

3

Clinical heterogeneity in monogenic chylomicronaemia.

Heidemann BE, Bemelmans RHH, Marais AD, Visseren FLJ, Koopal C. Heidemann BE, et al. Among authors: bemelmans rhh. BMJ Case Rep. 2022 Nov 24;15(11):e251411. doi: 10.1136/bcr-2022-251411. BMJ Case Rep. 2022. PMID: 36423940 Free PMC article.

4

The relationship between walking speed and changes in cardiovascular risk factors during a 12-day walking tour to Santiago de Compostela: a cohort study.

Bemelmans RH, Blommaert PP, Wassink AM, Coll B, Spiering W, van der Graaf Y, Visseren FL. Bemelmans RH, et al. BMJ Open. 2012 May 11;2(3):e000875. doi: 10.1136/bmjopen-2012-000875. Print 2012. BMJ Open. 2012. PMID: 22581795 Free PMC article.

5

Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease.

Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, Visseren FL; SMART Study Group. Bemelmans RH, et al. Obesity (Silver Spring). 2012 Apr;20(4):834-41. doi: 10.1038/oby.2011.321. Epub 2011 Oct 20. Obesity (Silver Spring). 2012. PMID: 22016101 Free article.

6

Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases.

Bemelmans RH, Wassink AM, van der Graaf Y, Nathoe HM, Vernooij JW, Spiering W, Visseren FL; SMART Study Group. Bemelmans RH, et al. Eur J Endocrinol. 2012 Apr;166(4):717-25. doi: 10.1530/EJE-11-1017. Epub 2012 Jan 27. Eur J Endocrinol. 2012. PMID: 22285702

7

Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease.

Vernooij JW, van der Graaf Y, Nathoe HM, Bemelmans RH, Visseren FL, Spiering W. Vernooij JW, et al. J Hypertens. 2013 Mar;31(3):492-99; discussion 499-500. doi: 10.1097/HJH.0b013e32835cd3cd. J Hypertens. 2013. PMID: 23303394

8

The risk of resting heart rate on vascular events and mortality in vascular patients.

Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, Visseren FL; SMARTStudy Group. Bemelmans RH, et al. Int J Cardiol. 2013 Sep 30;168(2):1410-5. doi: 10.1016/j.ijcard.2012.12.043. Epub 2013 Jan 8. Int J Cardiol. 2013. PMID: 23305859

9

[The resting heart rate].

Bemelmans RH, Visseren FL. Bemelmans RH, et al. Ned Tijdschr Geneeskd. 2014;158:A6931. Ned Tijdschr Geneeskd. 2014. PMID: 24666528 Review. Dutch.

10

The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease.

van Kruijsdijk RC, van der Graaf Y, Bemelmans RH, Nathoe HM, Peeters PH, Visseren FL; SMART Study Group. van Kruijsdijk RC, et al. Cancer Epidemiol. 2014 Dec;38(6):715-21. doi: 10.1016/j.canep.2014.09.004. Epub 2014 Oct 17. Cancer Epidemiol. 2014. PMID: 25448083

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page